Post by
420Cali on Nov 29, 2019 1:46pm
KHRN
CASH: ~$45m in capital goes along way in terms of generating revenue. The recent quarter represents good defense of that cash position, as per Canaccord report COMMERCIALIZATION: Colombia regulation has taken time to implement seems they are being very careful and selective about commercialization with the right parties. Khiron receiving first and only quota of any company gives a good indication for the governments support for the company. Ideally first medical sale to patents happens in next few months. This is a significant catalyst MARKETS: Entry into the US and Europe makes sense. I believe cannabis has taken this trade route from Colombia before? This is not a new conceptonly difference this time its legal and branded products! Margins should be good here TEAM: Management and board have relevant experience to execute this business plan across these markets. Lot of adults around the table VALUATION: I believe Khiron is a victim of seasonal tax selling with large financings done at $2.20 and $2.95. Get through this month and into the new year with continued positive developments, the company should perform well in relationship to broader market. Canaccord report suggests significant discount to $3.25 target This is not an investment recommendation. Due your own due diligence.